GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » PB Ratio
中文

Fusion Antibodies (LSE:FAB) PB Ratio : 1.56 (As of Apr. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-25), Fusion Antibodies's share price is £0.0375. Fusion Antibodies's Book Value per Share for the quarter that ended in Sep. 2023 was £0.02. Hence, Fusion Antibodies's PB Ratio of today is 1.56.

The historical rank and industry rank for Fusion Antibodies's PB Ratio or its related term are showing as below:

LSE:FAB' s PB Ratio Range Over the Past 10 Years
Min: 0.74   Med: 3.62   Max: 27.66
Current: 1.56

During the past 9 years, Fusion Antibodies's highest PB Ratio was 27.66. The lowest was 0.74. And the median was 3.62.

LSE:FAB's PB Ratio is ranked better than
66.26% of 1310 companies
in the Biotechnology industry
Industry Median: 2.38 vs LSE:FAB: 1.56

During the past 12 months, Fusion Antibodies's average Book Value Per Share Growth Rate was -75.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -41.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -27.90% per year.

During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Fusion Antibodies was 234.00% per year. The lowest was -41.80% per year. And the median was 13.40% per year.

Back to Basics: PB Ratio


Fusion Antibodies PB Ratio Historical Data

The historical data trend for Fusion Antibodies's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies PB Ratio Chart

Fusion Antibodies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
PB Ratio
Get a 7-Day Free Trial Premium Member Only 1.18 4.36 8.49 4.23 8.95

Fusion Antibodies Semi-Annual Data
Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.77 4.23 5.15 8.95 2.29

Competitive Comparison of Fusion Antibodies's PB Ratio

For the Biotechnology subindustry, Fusion Antibodies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fusion Antibodies's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's PB Ratio distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's PB Ratio falls into.



Fusion Antibodies PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Fusion Antibodies's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2023)
=0.0375/0.024
=1.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Fusion Antibodies  (LSE:FAB) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Fusion Antibodies PB Ratio Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusion Antibodies (LSE:FAB) Business Description

Traded in Other Exchanges
N/A
Address
1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 10-21-2022